RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of

Data presented by Dr. Dean Fennell in an oral presentation at the IASLC 2023 World Conference on Lung Cancer in SingaporeRS Oncology’s novel therapy RSO-021, a first-in-class inhibitor of the antioxidant protein PRX3, was shown to reverse many of the features associated with aggressive mesothelioma tumor growthCAMBR...

Related Keywords

Leicester ,United Kingdom ,Massachusetts ,United States ,Cambridge ,Cambridgeshire ,Vermont ,Singapore ,Brian Cunniff ,University Of Leicester ,University Of Vermont Cancer Center ,Cunniff Laboratory ,Dean Fennell ,Lung Cancer ,Vermont Cancer ,Achilles Heel ,Future Directions ,Spatial Transformation ,Mesothelioma Involves ,